文献速递慢阻肺

吗啡对晚期慢阻肺劳力性呼吸困难与运动耐力的影响:随机交叉试验

Effect of morphine on breathlessness and exercise endurance in advanced COPD: a randomised crossover trial.
PubMed 文献 · Eur Respir J · 2017-10-19

该随机交叉试验在20例晚期慢阻肺伴慢性呼吸困难综合征成人中比较口服即释吗啡与安慰剂对恒定负荷心肺运动试验中生理与感知反应的影响。吗啡使等时点劳力性呼吸困难降低1.2±0.4 Borg单位、运动耐力时间增加2.5±0.9分钟(均p≤0.014),并降低通气与呼吸频率;仅部分患者呼吸困难改善≥1 Borg单位。

要点

  • 口服即释吗啡可改善部分晚期慢阻肺患者的劳力性呼吸困难并延长运动耐力时间。
  • 吗啡在等时点降低通气量和呼吸频率,提示其可能通过调节呼吸驱动发挥作用。
  • 增量心肺运动试验因不耐受呼吸困难终止者更可能从吗啡中获益。

核心结论

  • 口服即释吗啡改善部分而非全部晚期慢阻肺成人的劳力性呼吸困难与运动耐力。
  • 实验室心肺运动试验中症状限制的定位可能有助于识别最可能从吗啡获益的患者。

研究设计与样本

  • 随机交叉试验,比较口服即释吗啡与安慰剂在恒定负荷心肺运动试验中的急性效应。
  • 纳入20例晚期慢阻肺伴慢性呼吸困难综合征成人。

主要发现

  • 与安慰剂相比,吗啡使等时点劳力性呼吸困难降低1.2±0.4 Borg单位(p≤0.014)。
  • 与安慰剂相比,吗啡使运动耐力时间增加2.5±0.9分钟(p≤0.014)。
  • 运动等时点,吗啡使通气量降低1.3±0.5 L·min-1、呼吸频率降低2.0±0.9次·min-1(均p≤0.041)。
  • 11例为应答者(等时点呼吸困难降低≥1 Borg单位),9例为非应答者(降低<1 Borg单位)。
  • 应答者中因不耐受呼吸困难终止增量心肺运动试验的比例高于非应答者:82% versus 33%(p=0.028)。

临床怎么用

  • 对晚期慢阻肺伴慢性呼吸困难综合征患者,可考虑口服即释吗啡以减轻劳力性呼吸困难并延长运动耐力。
  • 增量心肺运动试验中因不耐受呼吸困难终止的患者可能更可能从吗啡治疗中获益。

局限性

  • 样本量较小(20例),结果需在更大样本中验证。
  • 仅评估口服即释吗啡的急性效应,未涉及长期疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of the present study was to evaluate the effect of morphine on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease (COPD).In a randomised crossover trial, we compared the acute effect of immediate-release oral morphine versus placebo on physiological and perceptual responses during constant-load cardiopulmonary cycle exercise testing (CPET) in 20 adults with advanced COPD and chronic breathlessness syndrome.Compared with placebo, morphine reduced exertional breathlessness at isotime by 1.2±0.4 Borg units and increased exercise endurance time by 2.5±0.9 min (both p≤0.014). During exercise at isotime, morphine decreased ventilation by 1.3±0.5 L·min-1 and breathing frequency by 2.0±0.9 breaths·min-1 (both p≤0.041). Compared with placebo, morphine decreased exertional breathlessness at isotime by ≥1 Borg unit in 11 participants (responders) and by <1 Borg unit in nine participants (non-responders). Baseline participant characteristics, including pulmonary function and cardiorespiratory fitness, were similar between responders and non-responders. A higher percentage of responders versus non-responders stopped incremental CPET due to intolerable breathlessness: 82 versus 33% (p=0.028).Immediate-release oral morphine improved exertional breathlessness and exercise endurance in some, but not all, adults with advanced COPD. The locus of symptom-limitation on laboratory-based CPET may help to identify patients most likely to benefit from morphine.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Abdallah SJ, Wilkinson-Maitland C, Saad N, et al. Effect of morphine on breathlessness and exercise endurance in advanced COPD: a randomised crossover trial. Eur Respir J. 2017. PMID: 29051274. doi:10.1183/13993003.01235-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。